Author

S. Vaithiyalingam

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biophysics· 1 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:proteomics· 2 Approach:biophysical modeling· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:protein folding & dynamics· 1

Frequent Co-Authors

A. Abdolvahabi· 1 shared A. Abu-Zaid· 1 shared A. AlTahan· 1 shared A. Davidoff· 1 shared B. Bailey Cooke· 1 shared B. Young· 1 shared D. Currier· 1 shared D. Fernando· 1 shared

Activity by Year

2019-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Abdolvahabi

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Reduction of oligomer size modulates the competition between cluster formation and phase separation of the tumor suppressor SPOP

N. Sabri, M. J. Cuneo, M. R. Marzahn, J. Lee, J. J. Bouchard, S. Vaithiyalingam, M. B. Borgia, J. D. Schmit, T. Mittag

This study shows that reducing SPOP oligomer size shifts its function from cluster formation to phase separation, enhancing ubiquitination activity and providing insights into separation-of-function mutations.

bioRxiv · Feb 11, 2023Biophysics

Geldanamycin inhibits Jumonji histone lysine demethylase KDM4 and targets chimeric transcription factor PAX3-FOXO1

A. Abu-Zaid, S. Singh, W. LIN, J. Low, A. Abdolvahabi, B. Bailey Cooke, J. Bowling, S. Vaithiyalingam, J. Fang, D. Currier, M.-K. Yun, A. AlTahan, D. Fernando, J. Maier, H. Tillman, , J. YANG

This study identifies geldanamycin and its analog 17-DMAG as dual KDM/Hsp90 inhibitors effective against PAX3-FOXO1-driven rhabdomyosarcoma.

bioRxiv · Dec 11, 2019 · PreprintCancer Biology